Toggle Side Panel

Treatment for recurrent or metastatic cervical cancer

max
MariaPCC 29 June 2026

A treatment option is now available on the NHS for cervical cancer that has come back or spread to other parts of the body, following National Institute for Health and Care Excellence (NICE) final draft guidance. NICE has recommended cemiplimab (also called Libtayo and made by Regeneron) as an option for adults with recurrent or metastatic cervical cancer that has got worse during or after they’ve had platinum-based chemotherapy, and who have not had treatment with a type of medicine called an immunotherapy. Around 90 adults a year are expected to be eligible for this treatment.

Categories: News

Report

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to groups
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .
Keep up to date

Sign up to receive our daily news alerts straight to your inbox. Subscribe to our weekly newsletter containing a summary of the week’s news, blog and vote on our poll.

Weekly Newsletter

Daily news updates

Have a discussion

Help keep the conversation going between meetings by creating a forum to hold discussions with your members. It’s an easy way to manage and communicate with members.

Create a network

Create a network to share documents, knowledge and best practice with your colleagues. Set up a network to keep in touch with other people in your organisation or with shared interest groups across organisational boundaries.

Networks can be open to all or available only to a closed group defined by the administrator.

Join or create a network here.